An advisory panel of the US Centers for Disease Control and Prevention (CDC) on Thursday decided not to recommend boosters for younger adults, including healthcare workers, who live or work in institutions with high risk of contracting COVID-19, Reuters news agency reported on Friday.
The panel has only recommended a booster shot of the Pfizer (NYSE:PFE)/BioNTech (Nasdaq:BNTX) COVID-19 vaccine for Americans aged 65 and older and some adults with underlying medical conditions that put them at risk of severe disease.
For now, the panel has rejected additional doses for groups including healthcare workers, teachers and residents of homeless shelters and prisons, in part because of the difficulty of implementing such a proposal.
In addition to older Americans, the committee also recommended the booster shots for all adults over 50 with underlying conditions, as well as some 18- to 49-year-olds with those conditions, based on their individual risk profile. Those conditions include cancer, diabetes, certain heart conditions and chronic kidney disease and lung disorders.
The recommendations only cover people who received their second Pfizer/BioNTech shot at least six months earlier. This group is currently about 26 million people, including 13 million aged 65 or older, the CDC said.
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial
Pfizer and BioNTech receive EU regulatory backing for LP.8.1-adapted COVID-19 vaccine
Sanofi to acquire Vicebio for USD1.15bn to strengthen respiratory vaccine pipeline
Bavarian Nordic chikungunya vaccine enters Health Canada review process
SK bioscience submits IND for Phase 1/2 clinical trial of new influenza vaccine candidate
GC Biopharma secures Vietnamese approval for varicella vaccine BARYCELA
GSK announces submission of RSV vaccine Arexvy for FDA review
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Centivax raises USD45m to commercialise universal flu vaccine
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Valneva signs exclusive German vaccine distribution deal with CSL Seqirus